The Genetics of Ethambutol-Induced Optic Neuropathy: A Narrative Review

References

• Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol. 2013;3(1):37. doi:10.1016/j.jceh.2012.12.001.
   PubMedGoogle Scholar
• Sulis G, Roggi A, Matteelli A, Raviglione MC. Tuberculosis: epidemiology and control. Mediterr J Hematol Infect Dis. 2014;6(1):e2014070. doi:10.4084/mjhid.2014.070.
   PubMedGoogle Scholar
• Manikandan S. Treating tuberculosis: time to introduce fixed-dose drug combinations. J Young Pharm JYP. 2012;4(4):199–200. doi:10.4103/0975-1483.104362.
   PubMedGoogle Scholar
• World Health Organization, Stop TB Initiative (World Health Organization). Treatment of Tuberculosis: Guidelines. WHO Press: World Health Organization; 2010.
   Google Scholar
• Chaudhuri. Recent changes in technical and operational guidelines for tuberculosis control programme in India - 2016: a paradigm shift in tuberculosis control. J Assoc Chest Physicians. 2017;5(1):1.
   Google Scholar
• Gedik S, Azizler M, Akova YA, Atalay B, Caner H, Altinörs N. Ethambutol-Induced optic neuropathy in a patient with pituitary macroadenoma: case report. Adv Ther. 2003;20(6):319–323. doi:10.1007/BF02849797.
   PubMed Web of Science ®Google Scholar
• Wang MY, Sadun AA. Drug-Related mitochondrial optic neuropathies. J Neuroophthalmol. 2013;33(2):172–178. doi:10.1097/WNO.0b013e3182901969.
   PubMed Web of Science ®Google Scholar
• Oliveira C. Toxic-Metabolic and hereditary optic neuropathies. Contin Lifelong Learn Neurol. 2019;25(5):1265–1288. doi:10.1212/CON.0000000000000769.
   Google Scholar
• Teng D, Peng CX, Qian HY, Li L, Wang W, Wang JQ, et al. Structural impairment patterns in peripapillary retinal fiber layer and retinal ganglion cell layer in mitochondrial optic neuropathies. Int J Ophthalmol. 2018;11(10):1643–1648. doi:10.18240/ijo.2018.10.11.
   PubMed Web of Science ®Google Scholar
• Karmon G, Savir H, Zevin D, Levi J. Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment. Ann Ophthalmol. 1979;11:1013–1017.
   PubMed Web of Science ®Google Scholar
• Chowdhury B, Nagpaul AK, Chowdhury D. Leber’s hereditary optic neuropathy masquerading as ethambutol-induced optic neuropathy in a young male. Indian J Ophthalmol. 2006;54(3):218–219. doi:10.4103/0301-4738.27091.
   PubMedGoogle Scholar
• Fang J-T, Chen Y-C, Chang M-Y. Ethambutol-Induced optic neuritis in patients with end stage renal disease on hemodialysis: two case reports and literature review. Ren Fail. 2004;26(2):189–193. doi:10.1081/JDI-120038521.
   PubMed Web of Science ®Google Scholar
• Hwang J-M, Kim J, Park SS. Leber’s hereditary optic neuropathy mutations in ethambutol-induced optic neuropathy. J Neurol. 2003;250(1):87–89. doi:10.1007/s00415-003-0960-0.
   PubMed Web of Science ®Google Scholar
• Ikeda A, Ikeda T, Ikeda N, Kawakami Y, Mimura O. Leber’s hereditary optic neuropathy precipitated by ethambutol. Jpn J Ophthalmol. 2006;50(3):280–283. doi:10.1007/s10384-005-0308-7.
   PubMed Web of Science ®Google Scholar
• Ormerod LP, Skinner C, Wales J. Hepatotoxicity of antituberculosis drugs. Thorax. 1996;51(2):111–113. doi:10.1136/thx.51.2.111.
   PubMed Web of Science ®Google Scholar
• Singh A, Prasad R, Balasubramanian V, Gupta N, Gupta P. Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis. Clin Epidemiol Glob Health. 2015;3:S80–90. doi:10.1016/j.cegh.2015.10.005.
   Web of Science ®Google Scholar
• Tugwell P, James SL. Peripheral neuropathy with ethambutol. Postgrad Med J. 1972;48:667–670.
   PubMed Web of Science ®Google Scholar
• Guillet V, Chevrollier A, Cassereau J, Letournel F, Gueguen N, Richard L, et al. Ethambutol-Induced optic neuropathy linked to OPA1 mutation and mitochondrial toxicity. Mitochondrion. 2010;10(2):115–124. doi:10.1016/j.mito.2009.11.004.
   PubMed Web of Science ®Google Scholar
• Pradhan M, Sharp D, Best S, Vincent A, Vaphiades M. Drug-induced optic neuropathy—TB or not TB. Surv Ophthalmol. 2010;55(4):378–385. doi:10.1016/j.survophthal.2009.10.005.
   PubMed Web of Science ®Google Scholar
• Seo JH, Hwang JM, Park SS. Antituberculosis medication as a possible epigenetic factor of Leber’s hereditary optic neuropathy. Clin Exp Ophthalmol. 2010;38(4):363–366. doi:10.1111/j.1442-9071.2010.02240.x.
   PubMed Web of Science ®Google Scholar
• Fonkem E, Skordilis MA, Binkley EM, Raymer DS, Epstein A, Arnold WD, et al. Ethambutol toxicity exacerbating the phenotype of CMT2A2. Muscle Nerve. 2013;48(1):140–144. doi:10.1002/mus.23766.
   PubMed Web of Science ®Google Scholar
• Leibold JE. The ocular toxicity of ethambutol and its relation to dose*. Ann N Y Acad Sci. 1966;135(2):904–909. doi:10.1111/j.1749-6632.1966.tb45532.x.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care. World Health Organization; 2017:80.
   Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416. doi:10.1164/rccm.200604-571ST.
   PubMed Web of Science ®Google Scholar
• Lee EJ, Kim S-J, Choung HK, Kim JH, Yu YS. Incidence and clinical features of ethambutol-induced optic neuropathy in Korea. J Neuro-Ophthalmol off J North Am Neuro-Ophthalmol Soc. 2008;28(4):269–277. doi:10.1097/WNO.0b013e31818e3c6b.
   PubMed Web of Science ®Google Scholar
• Citron KM, Thomas GO. Ocular toxicity from ethambutol. Thorax. 1986;41(10):737–739. doi:10.1136/thx.41.10.737.
   PubMed Web of Science ®Google Scholar
• De Palma P, Franco F, Bragliani G, Michetti L, Marescotti A, Pirazzoli G, et al. The incidence of optic neuropathy in 84 patients treated with ethambutol. Metab Pediatr Syst Ophthalmol N Y N. 1989;12(1–3):80–82.
   PubMedGoogle Scholar
• Srivastava AK, Goel UC, Bajaj S, Singh KJ, Dwivedi NC, Tandon MP. Visual evoked responses in ethambutol induced optic neuritis. J Assoc Physicians India. 1997;45:847–849.
   PubMedGoogle Scholar
• Goyal JL, De Sarmi DE, Singh NP, Bhatia A. Evaluation of visual functions in patients on ethambutol therapy for tuberculosis: a prospective study. J Commun Dis. 2003;35:230–243.
   PubMedGoogle Scholar
• Hasenbosch RE, Alffenaar JWC, Koopmans SA, Kosterink JGW, van der Werf TS, van Altena R. Ethambutol-Induced optical neuropathy: risk of overdosing in obese subjects. Int J Tuberc Lung Dis off J Int Union Tuberc Lung Dis. 2008;12:967–971.
   PubMed Web of Science ®Google Scholar
• Chen H-Y, Lai S-W, Muo C-H, Chen P-C, Wang I-J. Ethambutol-Induced optic neuropathy: a nationwide population-based study from Taiwan. Br J Ophthalmol. 2012;96(11):1368–1371. doi:10.1136/bjophthalmol-2012-301870.
   PubMed Web of Science ®Google Scholar
• Chen S-C, Lin M-C, Sheu S-J. Incidence and prognostic factor of ethambutol-related optic neuropathy: 10-year experience in southern Taiwan. Kaohsiung J Med Sci. 2015;31(7):358–362. doi:10.1016/j.kjms.2015.05.004.
   PubMed Web of Science ®Google Scholar
• Yang HK, Park MJ, Lee J-H, Lee C-T, Park JS, Hwang J-M. Incidence of toxic optic neuropathy with low-dose ethambutol. Int J Tuberc Lung Dis off J Int Union Tuberc Lung Dis. 2016;20(2):261–264. doi:10.5588/ijtld.15.0275.
   PubMed Web of Science ®Google Scholar
• Mandal S, Saxena R, Dhiman R, Mohan A, Padhy SK, Phuljhele S, et al. Prospective study to evaluate incidence and indicators for early detection of ethambutol toxicity. Br J Ophthalmol. 2021;105(7):1024–1028. doi:10.1136/bjophthalmol-2020-316897.
   PubMed Web of Science ®Google Scholar
• Palomino JC, Martin A. Drug resistance mechanisms in mycobacterium tuberculosis. Antibiotics. 2014;3(3):317–340. doi:10.3390/antibiotics3030317.
   Google Scholar
• Abrahams KA, Besra GS. Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target. Parasitology. 2018;145(2):116–133. doi:10.1017/S0031182016002377.
   PubMed Web of Science ®Google Scholar
• Schubert K, Sieger B, Meyer F, Giacomelli G, Böhm K, Rieblinger A, et al. The antituberculosis drug ethambutol selectively blocks apical growth in CMN group bacteria. MBio. 2017;8(1):e02213–16. doi:10.1128/mBio.02213-16.
   PubMed Web of Science ®Google Scholar
• Chen R, Zhang Y, Tang S, Lv X, Wu S, Sun F, et al. The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a case-control study. J Clin Pharm Ther. 2015;40(1):110–115. doi:10.1111/jcpt.12211.
   PubMed Web of Science ®Google Scholar
• Chung H, Yoon YH, Hwang JJ, Cho KS, Koh JY, Kim J-G. Ethambutol-Induced toxicity is mediated by zinc and lysosomal membrane permeabilization in cultured retinal cells. Toxicol Appl Pharmacol. 2009;235(2):163–170. doi:10.1016/j.taap.2008.11.006.
   PubMed Web of Science ®Google Scholar
• Zhang X-H, Xie Y, Xu Q-G, Cao K, Xu K, Jin Z-B, et al. Mitochondrial mutations in ethambutol-induced optic neuropathy. Front Cell Dev Biol. 2021;9:754676. doi:10.3389/fcell.2021.754676.
   PubMed Web of Science ®Google Scholar
• Chen L, Liang Y. Optic nerve neuropathy by ethambutol toxicity. Chin J Tuberc Respir Dis. 1999;22:302–304.
   Google Scholar
• Shoubridge EA. Nuclear genetic defects of oxidative phosphorylation. Hum Mol Genet. 2001;10(20):2277–2284. doi:10.1093/hmg/10.20.2277.
   PubMed Web of Science ®Google Scholar
• DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med. 2003;348(26):2656–2668. doi:10.1056/NEJMra022567.
   PubMed Web of Science ®Google Scholar
• Levin LA. Superoxide generation explains common features of optic neuropathies associated with cecocentral scotomas. J Neuro-Ophthalmol off J North Am Neuro-Ophthalmol Soc. 2015;35(2):152–160. doi:10.1097/WNO.0000000000000250.
   PubMed Web of Science ®Google Scholar
• Sruthi S, Anuradha A. Ethambutol induced optic neuritis: a case series. Int J Basic Clin Pharmacol. 2019;9(1):207–210. doi:10.18203/2319-2003.ijbcp20195788.
   Google Scholar
• Buyske DA, Peets E, Sterling W. Pharmacological and biochemical studies on ethambutol in laboratory animals. Ann N Y Acad Sci. 1966;135(2):711–725. doi:10.1111/j.1749-6632.1966.tb45517.x.
   PubMed Web of Science ®Google Scholar
• Heng JE, Vorwerk CK, Lessell E, Zurakowski D, Levin LA, Dreyer EB. Ethambutol is toxic to retinal ganglion cells via an excitotoxic pathway. Invest Ophthalmol Vis Sci. 1999;40:190–196.
   PubMed Web of Science ®Google Scholar
• Yoon YH, Jung KH, Sadun AA, Shin HC, Koh JY. Ethambutol-Induced vacuolar changes and neuronal loss in rat retinal cell culture: mediation by endogenous zinc. Toxicol Appl Pharmacol. 2000;162(2):107–114. doi:10.1006/taap.1999.8846.
   PubMed Web of Science ®Google Scholar
• Carelli V, Ross-Cisneros FN, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res. 2004;23(1):53–89. doi:10.1016/j.preteyeres.2003.10.003.
   PubMed Web of Science ®Google Scholar
• Yu-Wai-Man P, Griffiths PG, Hudson G, Chinnery PF. Inherited mitochondrial optic neuropathies. J Med Genet. 2009;46(3):145–158. doi:10.1136/jmg.2007.054270.
   PubMed Web of Science ®Google Scholar
• Chevrollier A, Guillet V, Loiseau D, et al. Hereditary optic neuropathies share a common mitochondrial coupling defect. Ann Neurol. 2008;63(6):794–798. doi:10.1002/ana.21385.
   PubMed Web of Science ®Google Scholar
• WNasemann J, Zrenner E, Riedel KG. Recovery after severe ethambutol intoxication--psychophysical and electrophysiological correlations. Doc Ophthalmol Adv Ophthalmol. 1989;71(3):279–92.
   PubMed Web of Science ®Google Scholar
• Alexander C, Votruba M, Pesch UE, Thiselton DL, Mayer S, Moore A, et al. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet. 2000;26(2):211–215. doi:10.1038/79944.
   PubMed Web of Science ®Google Scholar
• Olichon A, Baricault L, Gas N, Guillou E, Valette A, Belenguer P, et al. Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J Biol Chem. 2003;278(10):7743–7746. doi:10.1074/jbc.C200677200.
   PubMed Web of Science ®Google Scholar
• Züchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet. 2004;36(5):449–451. doi:10.1038/ng1341.
   PubMed Web of Science ®Google Scholar
• Saxena R, Singh D, Phuljhele S, Kalaiselvan V, Karna S, Gandhi R, et al. Ethambutol toxicity: expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy. Indian J Ophthalmol. 2021;69(12):3734–3739. doi:10.4103/ijo.IJO_3746_20.
   PubMed Web of Science ®Google Scholar
• Chamberlain PD, Sadaka A, Berry S, Lee AG. Ethambutol optic neuropathy. Curr Opin Ophthalmol. 2017;28(6):545–551. doi:10.1097/ICU.0000000000000416.
   PubMed Web of Science ®Google Scholar
• Narang RK, Varma BMD. Ocular toxicity of Ethambutol (A clinical study). Indian J Ophthalmol. 1979;27:37.
   PubMedGoogle Scholar
• Choi SY, Hwang JM. Optic neuropathy associated with ethambutol in Koreans. Korean J Ophthalmol. 1997;11(2):106. doi:10.3341/kjo.1997.11.2.106.
   PubMedGoogle Scholar
• Schild HS, Fox BC. Rapid-Onset reversible ocular toxicity from ethambutol therapy. Am J Med. 1991;90(3):404–406. doi:10.1016/0002-9343(91)90588-O.
   PubMed Web of Science ®Google Scholar
• Boulanger Scemama E, Touitou V, Le Hoang P. Bitemporal hemianopia as presenting sign of severe ethambutol toxicity. J Fr Ophtalmol. 2013;36(9):e163–167. doi:10.1016/j.jfo.2012.12.008.
   PubMed Web of Science ®Google Scholar
• Melamud A, Kosmorsky GS, Lee MS. Ocular ethambutol toxicity. Mayo Clin Proc. 2003;78(11):1409–1411. doi:10.4065/78.11.1409.
   PubMed Web of Science ®Google Scholar
• Zoumalan CI, Sadun AA. Optical coherence tomography can monitor reversible nerve-fibre layer changes in a patient with ethambutol-induced optic neuropathy. Br J Ophthalmol. 2007;91(6):839–840. doi:10.1136/bjo.2006.107326.
   PubMed Web of Science ®Google Scholar
• Woung LC, Jou JR, Liaw SL. Visual function in recovered ethambutol optic neuropathy. J Ocul Pharmacol Ther off J Assoc Ocul Pharmacol Ther. 1995;11(3):411–419. doi:10.1089/jop.1995.11.411.
   PubMed Web of Science ®Google Scholar
• Sharma P, Sharma R. Toxic optic neuropathy. Indian J Ophthalmol. 2011;59(2):137.
   PubMed Web of Science ®Google Scholar
• Sheng W-Y, Su L-Y, Ge W, Wu S-Q, Zhu L-W. Analysis of structural injury patterns in peripapillary retinal nerve fibre layer and retinal ganglion cell layer in ethambutol-induced optic neuropathy. BMC Ophthalmol. 2021;21(1):132. doi:10.1186/s12886-021-01881-y.
   PubMed Web of Science ®Google Scholar
• Mehta S. Patterns of ethambutol ocular toxicity in extended use therapy. Cureus. 2019;11:e4408.
   PubMed Web of Science ®Google Scholar
• Lu PG, Kung NH, Van Stavern GP. Ethambutol optic neuropathy associated with enhancement at the optic chiasm. Can J Ophthalmol J Can Ophtalmol. 2017;52(5):e178–81. doi:10.1016/j.jcjo.2017.03.001.
   PubMed Web of Science ®Google Scholar
• Guerra R, Casu L. Hydroxycobalamin for ethambutol-induced optic neuropathy. Lancet Lond Engl. 1981;2(8256):1176. doi:10.1016/S0140-6736(81)90631-0.
   PubMed Web of Science ®Google Scholar
• Tsai RK, Lee YH. Reversibility of ethambutol optic neuropathy. J Ocul Pharmacol Ther off J Assoc Ocul Pharmacol Ther. 1997;13(5):473–477. doi:10.1089/jop.1997.13.473.
   PubMed Web of Science ®Google Scholar
• Nema N, Verma A, Singh K, Mehar V. Management of paradoxical response in pediatric tubercular meningitis with methylprednisolone. Middle East Afr J Ophthalmol. 2014;21(2):189–192. doi:10.4103/0974-9233.129775.
   PubMedGoogle Scholar
• Xu J, Dai Q, Wu S, Sheng W, Zhao S, Zhong L. Treatment of ethambutol-induced optic neuropathy by buqihuoxue formula combined with methycobal. Int J Clin Exp Med. 2017;10:7011–7015.
   Web of Science ®Google Scholar
• Si M, Li H, Chen Y, Peng H. Ethambutol and isoniazid induced severe neurotoxicity in a patient undergoing continuous ambulatory peritoneal dialysis. BMJ Case Rep. 2018;2018:bcr-2017–223187. doi:10.1136/bcr-2017-223187.
   Google Scholar
• Matsumoto T, Kusabiraki R, Arisawa A, Fujiki T, Noda A, Tanaka A, et al. Drastically progressive ethambutol-induced optic neuropathy after withdrawal of ethambutol: a case report and literature review. Intern Med Tokyo Jpn. 2021;60(11):1785–1788. doi:10.2169/internalmedicine.6178-20.
   Web of Science ®Google Scholar
• Şahin A, Kürşat Cingü A, Kaya S, Türkcü G, Arı Ş, Evliyaoğlu O, et al. The protective effects of caffeic acid phenethyl ester in isoniazid and ethambutol-induced ocular toxicity of rats. Cutan Ocul Toxicol. 2013;32(3):228–233. doi:10.3109/15569527.2012.759958.
   PubMed Web of Science ®Google Scholar